Prescription of fondaparinux in hospitalised patients

被引：11

作者：

Baroletti, Steven ^{[1
]}

Labreche, Matthew ^{[1
]}

Niles, Matthew ^{[2
]}

Fanikos, John ^{[1
]}

Goldhaber, Samuel Z. ^{[3
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Dept Pharm, Sch Med, Boston, MA 02115 USA

[2] Harvard Univ, Brigham & Womens Hosp, Venous Thromboembolism Res Grp, Sch Med, Boston, MA 02115 USA

[3] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, Boston, MA 02115 USA

来源：

THROMBOSIS AND HAEMOSTASIS | 2009年 / 101卷 / 06期

关键词：

Fondaparinux; antithrombotic agents; heparin-induced thrombocytopenia; HEPARIN-INDUCED-THROMBOCYTOPENIA; ACUTE PULMONARY-EMBOLISM; INITIAL TREATMENT; ENOXAPARIN; THERAPY;

D O I：

10.1160/TH09-01-0008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fondaparinux is an antithrombotic agent with unique properties that may offer benefit to patients beyond the current approved indications. To explore the off-label use versus approved use of fondaparinux, we initiated a single-center registry of fondaparinux use. During the 25-month study period, 219 patients were prescribed fondaparinux: 157 (71.7%) for prophylaxis and 62 (28.3%) patients for the treatment of thrombosis. When fondaparinux was used for prophylaxis in our registry, 94% of patients had documentation of heparin-induced thrombocytopenia (HIT). Fondaparinux warrants further evaluation in patients with HIT or suspected HIT In the meantime, its off-label use may exceed its use for FDA-approved indications.

引用

页码：1091 / 1094

页数：4

共 16 条

[1] Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes [J].

Baroletti, Steven ;

Piovella, Chiara ;

Fanikos, John ;

Labreche, Matthew ;

Lin, Jay ;

Goldhaber, Samuel Z. .

THROMBOSIS AND HAEMOSTASIS, 2008, 100 (06) :1130-1135

[2] Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep venous thrombosis -: A randomized trial [J].

Büller, HR ;

Davidson, BL ;

Decousus, H ;

Gallus, A ;

Gent, M ;

Piovella, F ;

Prins, MH ;

Raskob, G ;

Segers, AEM ;

Cariou, R ;

Leeuwenkamp, O ;

Lensing, AWA .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (11) :867-873

[3]

Büller HR, 2003, NEW ENGL J MED, V349, P1695

[4]

Gocke J, 2005, ESSENTIALS OF VASCULAR LABORATORY DIAGNOSIS, P184, DOI 10.1002/9780470987414.ch15

[5] Antithrombotic therapy for venous thromboembolic disease [J].

Kearon, Clive ;

Kahn, Susan R. ;

Agnelli, Giancarlo ;

Goldhaber, Samuel ;

Raskob, Gary E. ;

Comerota, Anthony J. .

CHEST, 2008, 133 (06) :454S-545S

[6] Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia [J].

Lobo, Bob ;

Finch, Christopher ;

Howard, Amanda ;

Minhas, Sohail .

THROMBOSIS AND HAEMOSTASIS, 2008, 99 (01) :208-214

[7] The synthetic pentasaccharide fondaparinux: First in the class of antithrombotic agents that selectively inhibit coagulation factor Xa [J].

Petitou, M ;

Duchaussoy, P ;

Herbert, JM ;

Duc, G ;

El Hajji, M ;

Branellec, JF ;

Donat, F ;

Necciari, J ;

Cariou, R ;

Bouthier, J ;

Garrigou, E .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (04) :393-402

[8] Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia [J].

Rauova, L ;

Poncz, M ;

McKenzie, SE ;

Reilly, MP ;

Arepally, G ;

Weisel, JW ;

Nagaswami, C ;

Cines, DB ;

Sachais, BS .

BLOOD, 2005, 105 (01) :131-138

[9] Spiral computed tomography for acute pulmonary embolism [J].

Schoepf, UJ ;

Goldhaber, SZ ;

Costello, P .

CIRCULATION, 2004, 109 (18) :2160-2167

[10] Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism [J].

Shetty, Ranjith ;

Seddighzadeh, Ali ;

Parasuraman, Sudha ;

Vallurupalli, Neelima G. ;

Gerhard-Herman, Marie ;

Goldhaber, Samuel Z. .

THROMBOSIS AND HAEMOSTASIS, 2007, 98 (06) :1384-1386

← 1 2 →